News | June 13, 2023
Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
UTD2 is the world's first oral epothilone microtubule inhibitor
UTD2 is the world's first oral epothilone microtubule inhibitor
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Nous-209 has been developed using the Nouscom's viral vector platform
Bridging the gap between histopathology and molecular pathology
From cancer research to diagnostic solutions
Subscribe To Our Newsletter & Stay Updated
